Background) Phage therapy is the use of bacterial viruses (phages) to treat bacterial 1 infections. Phages lack the broad host ranges of antibiotics, so individual phages are often used with 2 no prior history of use in treatment. Therapeutic phages are thus often chosen based on limited 3 criteria, sometimes merely an ability to plate on the pathogenic bacterium. It is possible that better 4 treatment outcomes might be obtained from an informed choice of phages. Here we consider whether 5 phages used to treat the bacterial infection in a patient might specifically evolve to improve treatment. 6 Phages recovered from the patient could then serve as a source of improved phages or cocktails for 7 use on subsequent patients. (Methods) With the aid of mathematical and computational models, we 8 explore this possibility for four phage properties expected to promote therapeutic success: in vivo 9 growth, phage decay rate, overcoming resistant bacteria, and enzyme activity to degrade protective 10 bacterial layers. (Results) Phage evolution only sometimes works in favor of treatment, and even in 11 those cases, intrinsic phage dynamics in the patient are usually not ideal. An informed use of phages 12
for convenience will be referred to as 'planktonic'), whereas aggregates are protected from phage attack. However, aggregates convert into planktonic cells and vice versa; this switching of states accommodates the observation that aggregate numbers are somewhat reduced by phage attack but 162 much less so than isolated cells [28] . Our formulation constitutes a refuge model [also true of 26, but 163 we present a more explicit refuge]. However, we conjecture that the types of phenotypic variation most relevant to infections will be 207 spatially structured, such as planktonic cells dominating liquid tissues, and biofilms, aggregates or 208 abscesses in solid tissues. With spatial structure, different phage types or mutants will differentially 209 amplify in patches of cells where they grow best. In these settings, phage evolution and competition 210 should often work loosely in favor of treatment, at least on a local level, but dynamical complexities 211 allow for exceptions.
212
With phage cocktails or in vivo evolution of phage mutants, the composition of actively growing 213 phages exuded from patients will typically change over time as bacterial densities are suppressed at 214 different rates in different locations. The cumulative phage composition should mirror the phages with 215 the biggest numerical effect on bacterial killing at the time. However, one dilemma faced in phage 216 collection from the patient is that the relative abundance of different phages in the collection need 217 not match phage importance to reduction of the patient's symptoms. If the bacteria responsible for 218 morbidity or maintenance of the infection are confined to small or semi-protected bacterial populations, 219 the patient's phage output may be dominated by phages that kill large numbers of bacteria in other 220 tissues that contribute only slightly to virulence. Phage evolution itself will be driven by growth on the 221 larger populations of bacteria in the host. As a consequence of these varied processes and possibilities,
222
there is no predicted time to harvest phages from one patient that would ensure maximum benefit for 223 use on subsequent patients.
224
Conclusions. Intrinsic processes of phage evolution work unambiguously in favor of treatment 225 when bacteria exist in a single, well-mixed state. When multiple bacterial phenotypic states exist 226 and are well mixed, phage evolution and cocktail competition can give rise to unintuitive outcomes 227 whereby phages are selected to avoid some bacteria. Spatial structure of bacterial states, as with 228 biofilms (aggregates or abscesses) versus planktonic cells, may align phage evolution with suppressing 229 bacterial numbers locally, but these processes are not easy to study and are not well understood in vivo.
230
Although encouraging, these results do little more than suggest an expected, qualitative direction 231 of evolution regarding treatment. They offer nothing on the speed or magnitude of infection clearance.
232
Nor do we have any sense of how much within-host evolution to expect, given a potentially short 233 duration of treatment. Deeper insight to the uses of in vivo evolution to improve treatment comes by 234 addressing specific phage characteristics, next.
235
Phage decay rates 236 Using two well-characterized tailed phages (λ and P22), Merril et al. [19] showed that (i) the 237 initial or 'wildtype' isolate of each phage was rapidly cleared from mice (in the absence of bacteria), 238 and (ii) mutants of each could be isolated that were cleared more slowly (the clearance rate evolved 239 to approximately 20% of the initial). The study further showed that the long-persisting phages were 240 advantageous in prophylactic therapy -administered in advance of the infection -presumably from 241 their ability to persist up to the time of bacterial introduction. The interval in which phage decay was 242 measured was short, less than a day after inoculation, too fast for adaptive immunity to develop in the 243 naive mice. The suggestion was that phage clearance was due to the reticuloendothelial system.
244
These results raise two questions. (i) Is the benefit of long-persisting phages large enough to affect Of the phage characteristics analyzed in this paper, this one experiences the simplest evolutionary process: each phage type and mutant evolves independently of other phages, and the selection does not involve frequency-or density-dependence. Simple calculations can be informative as a first step. Let phage survival follow exponential decay, e −wt for the 'wildtype' and e −mt for the mutant (m < w, with t in minutes). If the mutant starts at frequency p 0 , the ratio of the mutant to wildtype will change in time according to R(t):
(1) R(t) increases without bound over time, but only as long as both phage types are abundant enough to 250 approximate deterministic dynamics.
251
The time at which the mutant comprises half the phage population is approximately
For new mutations, the numerator will typically lie in the range of 10-20. Although this calculation 252 ignores phage amplification (which should have little impact on relative phage abundances in the 253 absence of other differences between the phages), this formula shows that the time for an initially rare 254 mutant to dominate the phage population depends on the reciprocal of its relative advantage (w − m).
255
Given that both rates must be positive (and w > m), the magnitude of w − m cannot exceed w. A 256 wild-type with a very low clearance rate (w << 1), cannot be quickly displaced even for a mutant that p 0 = 10 −6 requires just over 2 days for the mutant to comprise half the population. This may be a long 263 time to wait for any treatment benefit afforded by the mutant. Furthermore, if the phage population 264 was declining (e.g., unable to maintain itself), the phages might be too rare after 2 days to observe 265 any improvement in treatment from mutant ascendance. An interesting observation is that phages 266 engineered by phage display (engineered to carry exposed, short peptides on the outside of the virion) 267 may be particularly prone to rapid clearance [33], as if there is a strong selection to eliminate the 268 engineering.
269
When phages are used prophylactically, it is obvious that any benefit of reduced clearance must because now a mutant, slow-decaying phage may arise and could in principle take over the within-host 275 population rapidly. Were this the case, one could rely on within-host evolution to improve treatment.
276
To address this possibility, we rely on a numerical model ( Fig. 1 the pure, slowly-decaying phage (Fig. 1 ).
285
Conclusions. If the wildtype phage has a suitably high decay rate, evolving the phage to a lower . Thin orange curves are protected bacteria in refuges, thick blue curves are susceptible, planktonic bacteria. Dashed grey indicates the fast-decaying phage (P 0 , decay rate of 0.008 per min), dotted grey indicates the better, slow-decaying phage (P 1 , decay rate of 0.002 per min). The inset key (A) applies to all panels. All trials use the same bacterial growth parameters and initial bacterial densities (given in Appendix A1). When phage are present, they are first added at 3000 minutes and added every 3000 minutes thereafter. (A): Bacterial densities slowly increase in the absence of phages. (B): Treatment with 10 5 rapidly-decaying phages causes a sudden decline in free bacterial densities, a somewhat slower decline in aggregate bacteria. The system is approaching equilibrium in that phage and bacterial densities are being maintained. (C): The phage inoculum consists of 10 5 rapidly-decaying phage and 0.1 slowly-decaying phage, the latter value to represent mutation. The slowly-decaying phage ascends profoundly but then drops when bacterial densities are too low to sustain it. (D): the phage inoculum consists of just 10 5 slowly-decaying phage. There is a substantial difference between the treatments with a pure fast-decaying phage or a pure slow-decaying phage. The main effect of starting with a slow-decay phage instead of relying on within-host evolution lies in the early dynamics, although a modest lingering benefit is apparent. Parameter values and initial conditions are given in Appendix A1. Outcomes vary with parameter values, and the actual effect of within-host evolution or treatment with pre-evolved, slowly decaying phages would need to be evaluated for each specific application. recovered from a patient, as in D'Herelle's approach, may well have evolved lower decay rates and 292 could be used with subsequent patients. The ascent of resistant bacteria within the patient will typically be inimical to treatment success and 351 should be avoided. Furthermore, there remains the formal possibility that a phage-resistant bacterium 352 will have increased virulence, perhaps by becoming mucoid and thus less sensitive to immune system 353 components; however, reports of such outcomes so far seem to be lacking. Experimental work indicates 354 that evolution of bacterial resistance is a seemingly ubiquitous and easy response to a high abundance 355 of phages. From in vitro co-culture studies of phages grown on single bacterial strains in simple media, Periodic dosing is only moderately more useful in suppressing bacterial resistance than is relying on intrinsic dynamics. The model assumes two strains of bacteria, each in two states (solid colored curves) and two strains of phage (dashed gray); the inset legend in (A) applies throughout, with equations and parameters given in Appendix A2. The vertical axis gives density, the horizontal axis time (minutes). The phages differ in whether they can infect both bacteria (the 'broad' phage, given by P 1 ) or just one bacterium (the 'narrow' phage, given by P 0 ); the narrow phage has the advantage of a slightly higher adsorption rate. The bacterial strain given by blue and orange curves is sensitive to both phages, the other (green and pink curves) is resistant to the narrow phage. Each bacterium exists both planktonically (thick curves) and in aggregates (thin curves), with aggregates being protected from all phages. The two bacteria differ only in sensitivity to the phages. (A): Growth of the bacteria in the absence of phages. (B): Both phages are introduced at time t=1000 at a density of 10 5 but are considered to be extinct when densities drop below 0.1. They have a rapid effect of driving the sensitive bacterial strain to low numbers, allowing the resistant bacterium to become the majority. Both phages are lost when the bacterial density is too low to sustain them, and all bacteria begin to recover, maintaining their relative abundances. (C): The same as in (B), except that phages are never considered to be extinct. The broad phage eventually rebounds in response to the high numbers of 'resistant' bacteria, and it suppresses both strains. (D): A cocktail of both phages is applied, each at a dose of 10 5 (time 1000) and then each at a dose of 10 7 (times 4000 and 7000). The narrow-host range phage gains early because of its superior adsorption rate. Resistant bacteria eventually ascend and allow the broad phage to maintain itself. Note that there is a substantial lag before the broad phage dominates. (E) The same as in (D), but the inocula at times 4000 and 7000 are increased to 10 9 of the broad phage. All bacteria are now pushed to near extinction.
Treatment with a single phage known to be resistance-proof appears to be the surest way to maintain a enzymes may profoundly help clear and infection, but this benefit does not help maintain the phages not representative of phage therapy patients [2] . We instead offer two models of ordinary differential 541 equations that deviate from the standard model and can generate some key outcomes mirroring those 542 of observed with phage therapy: bacteria exist in protected states, phage may slowly decay during 543 treatment, and multiple dosing may be required [2] . Although our models explicitly include many 544 components (minimally 4 variables and 9 parameters), they is proposed heuristically in that they 545 cannot be empirically parameterized. Instead, many parameters need be chosen so that the baseline 546 behavior allows phage to have only a moderate effect on bacterial densities in the short term, and 547 indeed for some trials, that multiple phage inoculations are needed to depress bacterial densities 548 to low levels. Any numerical trial of this model is useful chiefly in illustrating possibilities that are 549 incompatible with the standard model. Parameter values used in Fig. 1 are: k 0 , k 1 = 3 × 10 −9 , d 0 = 0.008, d 1 = 0.002, d B = 0.001, 552 b 0 , b 1 = 50, c = 2.5, ρ = 0.0018, β = 5 × 10 −4 . Initial bacterial densities are: B(0) = 2 × 10 5 , 553 B A (0) = 8 × 10 4 .
550

A1. One bacterial strain with two bacterial states and two phages 551Ḃ
A = − ρB A + βB (A1) B = ρcB A − k 0 P 0 B − k 1 P 1 B − d B Ḃ P 0 = b 0 k 0 BP 0 − d 0 P 0 P 1 = b 1 k 1 BP 1 − d 1 P 1 .
554
A2. Two bacterial states with two bacterial states and two phages 555
This model is similar to that in A1, except that it adds a second strain of bacteria, one that is 556 resistant in the planktonic state, necessarily also resistant as aggregates. To keep the emphasis on the 557 effect of resistance, many of the same parameter values are used for the two types of bacteria and for 558 phage infection of the bacteria.
Only variables that differ from the above are defined here. Parameters are the same as above in 
